Efficacy and safety of empegfilgrastim, a novel pegylated G-CSF: Results of complete analysis after 4 cycles of myelosuppressive chemotherapy in phase III double-dummy randomized clinical study.

Authors:

Abstract
E20735 Background: Empegfilgrastim is an innovator drug product of pegylated G-CSF indicated for prophylaxis of neutropenia in patients receiving myelosuppressive chemotherapy. Methods: Objective was to compare safety and efficacy of a single dose of empegfilgrastim and daily dosing of filgrastim in patients receiving docetaxel 75 mg/m2 + doxorubicin 50 mg/m2. 135 patients with breast cancer were randomly assigned at a ratio of 1:1:1 to receive either single s.c. injection of empegfilgrastim at doses of 6 mg or 7.5 mg, or daily s.c. injections of filgrastim at a dose of 5 mcg/kg (until ANC ≥ 10x109/L). Results: At the cycle 1 mean duration of grade 4 neutropenia (primary endpoint) was significantly shorter in both empegfilgrastim groups: 0,905, 0,791 and 1,725 days in 6 mg, 7.5 mg and filgrastim groups, correspondingly. Mean difference in duration of grade 4 neutropenia between filgrastim and 7.5 mg groups was -0,934 d (95% CI -1,504 to -0,364 d) (p < 0,05). During the next 3 cycles duration of grade 4 neutropenia was also significantly shorter in both empegfilgrastim groups: cycle 2 (0.452, 0.326 and 0.925 d), cycle 3 (0.244, 0.310 and 0.641 d), cycle 4 (0.195, 0.475 and 0.892 d) (p < 0.05). Bacterial infections were observed only in 4 patients from filgrastim group, all patients were treated with oral anti-infective drugs. Empegfilgrastim at both doses was as safe and well tolerated as daily filgrastim administration. Most AEs were associated with chemotherapy. Frequency of G-CSF-specific reactions as all other AEs was equivalent in all groups: myalgia (7.14%, 4.65% and 4.65%), arthralgia (14.29%, 6.98% and 6.98%), ossalgia (9.52%, 9.30% and 4.65%), local reactions (7.14%, 2.33% and 2.33%). Conclusions: The results of this study demonstrated therapeutic superiority of empegfilgrastim, especially at a dose of 7.5 mg, compared to filgrastim. Clinical trial information: NCT02104830.